There were 1,012 press releases posted in the last 24 hours and 426,936 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image